Every 10-Q that Optimizerx Corp (OPRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OPRX filings page.
OptimizeRx Corporation reported weaker results for the three and six months ended June 30, 2026. Net revenue fell 30% in Q2 to $20.5 million and 21% year to date to $40.3 million, largely due to the wind-down of a low-margin managed service program and the absence of revenue from a customer that represented about 10% of 2025 revenue. Macroeconomic pressures and pricing dynamics also weighed on demand.
Despite lower revenue, cost of revenues dropped sharply, improving gross margin as the business mix shifted toward higher-margin solutions. Total expenses declined about 20% year over year in both Q2 and year to date, reflecting efficiency initiatives, though stock-based compensation rose due to accelerated vesting tied to terminations. The company posted a Q2 net loss of $0.7 million versus a prior-year profit and a six‑month net loss of $1.2 million.
Operating cash flow remained solid at $8.1 million in the first half. OptimizeRx refinanced its debt with a new $35 million credit facility, leaving $19.7 million outstanding on the term loan at June 30, 2026 and an undrawn $10 million revolver. Cash and equivalents were $24.1 million and working capital was $44.4 million. Management continues to remediate a material weakness in internal control related to data from one third‑party service provider.
OptimizeRx reported a smaller quarterly loss as it improved margins despite lower revenue. Net revenue for the three months ended March 31, 2026 was $19,844, down 10% from $21,928 a year earlier, mainly due to the wind-down of a low-margin managed service program and reduced spend from a major customer.
Expenses fell 19% to $19,448, driven by a sharp drop in cost of revenues to $4,912, or about 25% of revenue, versus $8,584 previously. Income from operations was $396 compared with a loss of $2,102, and net loss narrowed to $495 from $2,199.
Cash and cash equivalents were $20,169 and working capital was $45,706 as of March 31, 2026. Long-term debt totaled $23,598 under a term loan bearing 12.4% interest, which the company refinanced on May 7, 2026 with a new $25,000 term loan and a $10,000 revolving facility at SOFR plus 1.75–2.5%. There were 18,765,075 common shares outstanding as of April 29, 2026. Management continues to work on remediating a remaining material weakness related to controls over data from one third-party service organization.
OptimizeRx (OPRX) reported stronger Q3 2025 results. Net revenue reached $26.067 million, up 22% year over year, as DTC and DAAP sales expanded. Gross margin improved to 67.2% from 63.1%, lifting operating income to $2.05 million versus an $8.56 million loss a year ago. Net income was $0.779 million ($0.04 diluted EPS).
For the first nine months, revenue rose 29% to $77.190 million and net income was $0.112 million, a turnaround from a $20.032 million loss in 2024. Interest expense declined alongside a lower average Term Loan balance. Operating cash flow increased to $11.627 million, and cash stood at $19.519 million.
Balance sheet health improved: total liabilities fell to $48.058 million and stockholders’ equity rose to $122.263 million. The Term Loan balance was $28.790 million at September 30, 2025, with a subsequent $2.0 million repayment on October 29 reducing it to $26.790 million. The company highlighted a 120% net revenue retention and continued margin benefits from solution and channel mix.
Common shares outstanding were 18,640,652 as of October 24, 2025.
OptimizeRx Corporation (OPRX) reported stronger quarterly results driven by growth in DTC and DAAP offerings. Net revenue rose 55% year-over-year to $29,195 (in thousands) for the three months ended June 30, 2025 and increased 33% to $51,123 for the six months ended June 30, 2025, reflecting higher direct-to-consumer and AI-driven audience activation sales. Gross margin improved to 63.8% for the quarter as cost-of-revenue as a percentage of sales declined to ~36% due to solution and channel mix.
The company delivered GAAP net income of $1,532 for Q2 2025 versus a loss of $4,008 in Q2 2024, produced $8,425 of operating cash flow in the six months, and reduced long-term debt net to $25,127 with a Term Loan outstanding of $29,290. Management remains covenant-compliant but carries significant Term Loan interest (13.1% rate reported) and future principal due in 2027. A previously identified material weakness in controls over third-party data is being remediated.